Interquartile Range

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 224499 Experts worldwide ranked by ideXlab platform

Mirela Jobim De Azevedo - One of the best experts on this subject based on the ideXlab platform.

  • improvement of the metabolic syndrome profile by soluble fibre guar gum in patients with type 2 diabetes a randomised clinical trial
    British Journal of Nutrition, 2013
    Co-Authors: Valesca Dallalba, Flavia Moraes Silva, Juliana Pecanha Antonio, Thais Steemburgo, Caroline Persh Royer, Jussara Carnevale De Almeida, Jorge Luiz Gross, Mirela Jobim De Azevedo
    Abstract:

    : A diet rich in fibre seems to protect against the metabolic syndrome (MetS), but there is scarce information about the role of fibre intake in patients with the MetS and diabetes. The aim of the present study was to evaluate the effects of soluble fibre from partially hydrolysed guar gum (PHGG) on the MetS and cardiovascular risk factors in patients with type 2 diabetes. In the present randomised controlled clinical trial, forty-four patients with type 2 diabetes (males 38·6 %, age 62 (SD 9) years, diabetes duration 14·2 (SD 9·6) years) and the MetS underwent clinical, laboratory and dietary evaluations at baseline, 4 and 6 weeks. All patients followed their usual diet and the intervention group (n 23) received an additional 10 g/d of PHGG. In the intervention group, waist circumference (WC), glycated Hb (HbA1c), 24 h urinary albumin excretion (UAE) and serum trans-fatty acids (FA) were reduced in comparison with baseline after 4 and 6 weeks: WC 103·5 (SD 9·5) to 102·1 (SD 10) to 102·3 (SD 9·7) cm; HbA1c 6·88 (SD 0·99) to 6·64 (SD 0·94) to 6·57 (SD 0·84) %; 24 h UAE 6·8 (Interquartile Range 3·0-17·5) to 4·5 (Interquartile Range 3·0-10·5) to 6·2 (Interquartile Range 3·0-9·5) mg; trans-FA 71 (Interquartile Range 46-137) to 67 (Interquartile Range 48-98) to 57 (Interquartile Range 30-110) mg/l (P< 0·05 for all). The only change in the control group was weight reduction: 77·0 (SD 13·5) to 76·2 (SD 13·3) to 76·1 (SD 13·4) kg (P= 0·005). Other MetS components (blood pressure, TAG, HDL-cholesterol, fasting plasma glucose), total and LDL-cholesterol, C-reactive protein and endothelin-1 did not change in either group. In patients with type 2 diabetes and the MetS, the addition of PHGG to the usual diet improved cardiovascular and metabolic profiles by reducing WC, HbA1c, UAE and trans-FA.

Peter B Berger - One of the best experts on this subject based on the ideXlab platform.

  • timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin
    American Journal of Cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S. Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of stent thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced stent thrombosis after successful coronary stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from stent implantation to stent thrombosis in the ticlopidine and aspirin group was 12 hours (Interquartile Range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (Interquartile Range 21 to 68 hours) (p <0.0001). There was no significant difference between the timing of stent thrombosis in patients treated with abciximab in addition to ticlopidine and aspirin (median 17 hours, Interquartile Range 6 to 29) versus ticlopidine and aspirin patients who did not receive abciximab (median 11 hours, Interquartile Range 9 to 12, p = 0.57). Thus, in patients who receive coronary stents, stent thrombosis occurs much earlier after the procedure in patients treated with ticlopidine and aspirin than in patients treated with anticoagulation therapy.

Valesca Dallalba - One of the best experts on this subject based on the ideXlab platform.

  • improvement of the metabolic syndrome profile by soluble fibre guar gum in patients with type 2 diabetes a randomised clinical trial
    British Journal of Nutrition, 2013
    Co-Authors: Valesca Dallalba, Flavia Moraes Silva, Juliana Pecanha Antonio, Thais Steemburgo, Caroline Persh Royer, Jussara Carnevale De Almeida, Jorge Luiz Gross, Mirela Jobim De Azevedo
    Abstract:

    : A diet rich in fibre seems to protect against the metabolic syndrome (MetS), but there is scarce information about the role of fibre intake in patients with the MetS and diabetes. The aim of the present study was to evaluate the effects of soluble fibre from partially hydrolysed guar gum (PHGG) on the MetS and cardiovascular risk factors in patients with type 2 diabetes. In the present randomised controlled clinical trial, forty-four patients with type 2 diabetes (males 38·6 %, age 62 (SD 9) years, diabetes duration 14·2 (SD 9·6) years) and the MetS underwent clinical, laboratory and dietary evaluations at baseline, 4 and 6 weeks. All patients followed their usual diet and the intervention group (n 23) received an additional 10 g/d of PHGG. In the intervention group, waist circumference (WC), glycated Hb (HbA1c), 24 h urinary albumin excretion (UAE) and serum trans-fatty acids (FA) were reduced in comparison with baseline after 4 and 6 weeks: WC 103·5 (SD 9·5) to 102·1 (SD 10) to 102·3 (SD 9·7) cm; HbA1c 6·88 (SD 0·99) to 6·64 (SD 0·94) to 6·57 (SD 0·84) %; 24 h UAE 6·8 (Interquartile Range 3·0-17·5) to 4·5 (Interquartile Range 3·0-10·5) to 6·2 (Interquartile Range 3·0-9·5) mg; trans-FA 71 (Interquartile Range 46-137) to 67 (Interquartile Range 48-98) to 57 (Interquartile Range 30-110) mg/l (P< 0·05 for all). The only change in the control group was weight reduction: 77·0 (SD 13·5) to 76·2 (SD 13·3) to 76·1 (SD 13·4) kg (P= 0·005). Other MetS components (blood pressure, TAG, HDL-cholesterol, fasting plasma glucose), total and LDL-cholesterol, C-reactive protein and endothelin-1 did not change in either group. In patients with type 2 diabetes and the MetS, the addition of PHGG to the usual diet improved cardiovascular and metabolic profiles by reducing WC, HbA1c, UAE and trans-FA.

Camila Pereira Leguisamo - One of the best experts on this subject based on the ideXlab platform.

  • Qualidade de vida de indivíduos com doença renal crônica terminal submetidos à hemodiálise Quality of life in individuals with end-stage chronic kidney disease undergoing hemodialysis
    2020
    Co-Authors: Daiana Moreira Mortari, Marice Regina Menta, Kátia Bilhar Scapini, Carla Wouters, Franco Rockembach, Alaour Candida Duarte, Camila Pereira Leguisamo
    Abstract:

    Aims: To evaluate the quality of life of end-stage chronic kidney disease individuals who underwent hemodialysis. Methods: A cross-sectional study included individuals with end-stage chronic kidney disease diagnosis, who underwent hemodialysis at Hospital de Passo Fundo, Rio Grande do Sul, Brazil. The quality of life was assessed by the Medical Outcomes Study Questionaire 36 - Item Short Form Health Survey (SF-36). Categorical variables were described as absolute and relative frequency and numerical variable as mean ± standard deviation or median and interquartil Range. The correlation between age, time of dialysis and the SF-36 domains were analyzed by Spearman’s rho test and Mann-Whitney test. Results: From the 49 individuals, 26 (53%) were male. The mean age was 51.5±14.4 years. The scores for quality of life in the SF-36 scales were: Role-Physical: median 0 (Interquartile Range 0-100); General Health: median 52 (Interquartile Range 41-100); Physical Functioning: median 60 (Interquartile Range 35-77.5); RoleEmotional: median 66.6 (Interquartile Range 0-100); Vitality: median 70 (Interquartile Range 40-80); Social Functioning: median 87.5 (Interquartile Range 50-100); Bodily Pain: median 72 (Interquartile Range 41-100); and Mental Health: median 72 (Interquartile Range 42-88). There was no correlation between quality of life and the studied variables, and no differences according to gender. Conclusions: Patients with end-stage chronic kidney disease undergoing hemodialysis presented a reduction in the quality of life scores, particularly in the General Health and Role-Physical scales of the SF-36.

  • Quality of life in individuals with end-stage chronic kidney disease undergoing hemodialysis [Abstract in English]
    2010
    Co-Authors: Daiana Moreira Mortari, Marice Regina Menta, Kátia Bilhar Scapini, Camila Pereira Leguisamo, Carla Wouters Franco Rockembach, Alaour Candida Duarte
    Abstract:

    AIMS: To evaluate the quality of life of end-stage chronic kidney disease individuals who underwent hemodialysis. METHODS: A cross-sectional study included individuals with end-stage chronic kidney disease diagnosis, who underwent hemodialysis at Hospital de Passo Fundo, Rio Grande do Sul, Brazil. The quality of life was assessed by the Medical Outcomes Study Questionaire 36 - Item Short Form Health Survey (SF-36). Categorical variables were described as absolute and relative frequency and numerical variable as mean ± standard deviation or median and interquartil Range. The correlation between age, time of dialysis and the SF-36 domains were analyzed by Spearman’s rho test and Mann-Whitney test. RESULTS: From the 49 individuals, 26 (53%) were male. The mean age was 51.514.4 years. The scores for quality of life in the SF-36 scales were: Role-Physical: median 0 (Interquartile Range 0-100); General Health: median 52 (Interquartile Range 41-100); Physical Functioning: median 60 (Interquartile Range 35-77.5); Role-Emotional: median 66.6 (Interquartile Range 0-100); Vitality: median 70 (Interquartile Range 40-80); Social Functioning: median 87.5 (Interquartile Range 50-100); Bodily Pain: median 72 (Interquartile Range 41-100); and Mental Health: median 72 (Interquartile Range 42-88). There was no correlation between quality of life and the studied variables, and no differences according to gender. CONCLUSION: Patients with end-stage chronic kidney disease undergoing hemodialysis presented a reduction in the quality of life scores, particularly in the General Health and Role-Physical scales of the SF-36.

Alaour Candida Duarte - One of the best experts on this subject based on the ideXlab platform.

  • Qualidade de vida de indivíduos com doença renal crônica terminal submetidos à hemodiálise Quality of life in individuals with end-stage chronic kidney disease undergoing hemodialysis
    2020
    Co-Authors: Daiana Moreira Mortari, Marice Regina Menta, Kátia Bilhar Scapini, Carla Wouters, Franco Rockembach, Alaour Candida Duarte, Camila Pereira Leguisamo
    Abstract:

    Aims: To evaluate the quality of life of end-stage chronic kidney disease individuals who underwent hemodialysis. Methods: A cross-sectional study included individuals with end-stage chronic kidney disease diagnosis, who underwent hemodialysis at Hospital de Passo Fundo, Rio Grande do Sul, Brazil. The quality of life was assessed by the Medical Outcomes Study Questionaire 36 - Item Short Form Health Survey (SF-36). Categorical variables were described as absolute and relative frequency and numerical variable as mean ± standard deviation or median and interquartil Range. The correlation between age, time of dialysis and the SF-36 domains were analyzed by Spearman’s rho test and Mann-Whitney test. Results: From the 49 individuals, 26 (53%) were male. The mean age was 51.5±14.4 years. The scores for quality of life in the SF-36 scales were: Role-Physical: median 0 (Interquartile Range 0-100); General Health: median 52 (Interquartile Range 41-100); Physical Functioning: median 60 (Interquartile Range 35-77.5); RoleEmotional: median 66.6 (Interquartile Range 0-100); Vitality: median 70 (Interquartile Range 40-80); Social Functioning: median 87.5 (Interquartile Range 50-100); Bodily Pain: median 72 (Interquartile Range 41-100); and Mental Health: median 72 (Interquartile Range 42-88). There was no correlation between quality of life and the studied variables, and no differences according to gender. Conclusions: Patients with end-stage chronic kidney disease undergoing hemodialysis presented a reduction in the quality of life scores, particularly in the General Health and Role-Physical scales of the SF-36.

  • Quality of life in individuals with end-stage chronic kidney disease undergoing hemodialysis [Abstract in English]
    2010
    Co-Authors: Daiana Moreira Mortari, Marice Regina Menta, Kátia Bilhar Scapini, Camila Pereira Leguisamo, Carla Wouters Franco Rockembach, Alaour Candida Duarte
    Abstract:

    AIMS: To evaluate the quality of life of end-stage chronic kidney disease individuals who underwent hemodialysis. METHODS: A cross-sectional study included individuals with end-stage chronic kidney disease diagnosis, who underwent hemodialysis at Hospital de Passo Fundo, Rio Grande do Sul, Brazil. The quality of life was assessed by the Medical Outcomes Study Questionaire 36 - Item Short Form Health Survey (SF-36). Categorical variables were described as absolute and relative frequency and numerical variable as mean ± standard deviation or median and interquartil Range. The correlation between age, time of dialysis and the SF-36 domains were analyzed by Spearman’s rho test and Mann-Whitney test. RESULTS: From the 49 individuals, 26 (53%) were male. The mean age was 51.514.4 years. The scores for quality of life in the SF-36 scales were: Role-Physical: median 0 (Interquartile Range 0-100); General Health: median 52 (Interquartile Range 41-100); Physical Functioning: median 60 (Interquartile Range 35-77.5); Role-Emotional: median 66.6 (Interquartile Range 0-100); Vitality: median 70 (Interquartile Range 40-80); Social Functioning: median 87.5 (Interquartile Range 50-100); Bodily Pain: median 72 (Interquartile Range 41-100); and Mental Health: median 72 (Interquartile Range 42-88). There was no correlation between quality of life and the studied variables, and no differences according to gender. CONCLUSION: Patients with end-stage chronic kidney disease undergoing hemodialysis presented a reduction in the quality of life scores, particularly in the General Health and Role-Physical scales of the SF-36.